Head-to-head · WeighScore
Cora Health vs Zealthy
The verdict
Cora Health takes it — 72.2/100 to 46.7/100.
Cora Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cora Health is a direct-to-consumer telehealth platform offering compounded semaglutide ($99–$175/mo) and tirzepatide ($135–$225/mo) with flat per-tier pricing — no surcharge as your dose escalates.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Cora Health | Zealthy |
|---|---|---|
| WeighScore | 72.2/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #81 | #496 |
| Semaglutide | $175/mo | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $225/mo | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #81 · C
Strengths
- Two named 503A compounding pharmacy partners disclosed on first-party pages (Hallandale Pharmacy + VialsRx)
- Hallandale Pharmacy is PCAB-accredited and operating since 2003 (independently verified)
- LegitScript Certified (seal ID 49690100 in footer)
- Flat per-tier pricing — no dose-escalation surcharge
- Annual commitment delivers $99/mo semaglutide and $135/mo tirzepatide
Where it loses points
- Compounded medications are not FDA-approved and not therapeutically equivalent to Wegovy/Zepbound
- Leanio Health LLC has zero independent operating-history footprint (no BBB, no press, likely <12 months old)
- Lowest advertised prices require 12-month commitment with no partial refunds
- No brand-name Wegovy/Zepbound or oral GLP-1 (orforglipron/Rybelsus) options
- Founder names and funding undisclosed on site
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.